NEW YORK and RESEARCH TRIANGLE PARK, N.C., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will present at the 10th Annual SVB Leerink Global Healthcare Conference taking place February 22-26, 2021. Details on the presentation can be found below.
Company management will also participate in one-on-one investor meetings at the conference.
About Sio Gene Therapies
Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. Our current pipeline of clinical-stage candidates includes the first potentially curative AAV-based gene therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal pediatric conditions caused by single gene deficiencies. We are also expanding the reach of gene therapy to highly prevalent conditions such as Parkinsons disease, which affects millions of patients globally. Led by an experienced team of gene therapy development experts, and supported by collaborations with premier academic, industry and patient advocacy organizations, Sio is focused on accelerating its candidates through clinical trials to liberate patients with debilitating diseases through the transformational power of gene therapies. For more information, visit http://www.siogtx.com.
Contacts:
Media
Josephine Belluardo, Ph.D. LifeSci Communications(646) 751-4361jo@lifescicomms.cominfo@siogtx.com
Investors and Analysts
Parag V. Meswani, Pharm.D.Sio Gene Therapies Inc.Chief Commercial Officerinvestors@siogtx.com
Continued here:
Sio Gene Therapies to Present at the 10th Annual SVB Leerink Global Healthcare Conference - GlobeNewswire
Related Post
- A Year of DMD Gene Therapy Trial Failures - AJMC.com Managed Markets Network - November 3rd, 2024
- Hemophilia B: Gene Therapy Shows Promise - Medscape - November 3rd, 2024
- Around the Helix: Cell and Gene Therapy Company Updates October 30, 2024 - CGTLive - November 3rd, 2024
- 2024 PharmaVoice 100s: Cell and Gene Therapy Pioneers - PharmaVoice - November 3rd, 2024
- Cell therapy weekly: support for commercialization of complex therapies - RegMedNet - November 3rd, 2024
- Lexeo shares early data on Alzheimers gene therapy - Endpoints News - November 3rd, 2024
- Medicaid Aiming to Improve Patient Access to High-Cost Therapies - AJMC.com Managed Markets Network - November 3rd, 2024
- The Significance of Gene Therapy in Neuromuscular Medicine at the 2025 MDA Conference: Paul Melmeyer, MPP - Neurology Live - November 3rd, 2024
- OHSU researchers identify gene that could be key to future HIV vaccine - OHSU News - November 3rd, 2024
- Purespring gene therapy reduces kidney scarring in mice and is stably expressed in pigs - Fierce Biotech - November 3rd, 2024
- Data Roundup: October 2024 Features Update for TCR-Based Autologous Cell Therapy in Melanoma, the First Clinical Demonstration of Therapeutic RNA... - November 3rd, 2024
- NewBiologix Launches Xcell to Accelerate, Optimize, and Scale Gene and Cell Therapy Production - Business Wire - November 3rd, 2024
- Vertex Pharmaceuticals and CRISPR Therapeutics Casgevy: the 200 Best Inventions of 2024 - TIME - November 3rd, 2024
- Addressing gene and cell therapy commercialization challenges - TechTarget - November 3rd, 2024
- University of Pennsylvania gene therapy spinout Interius BioTherapeutics doses patient, achieves CAR therapy first - The Business Journals - November 3rd, 2024
- Roche will aim to tackle gene therapy challenges through Dyno deal - The Pharma Letter - November 3rd, 2024
- Behind the Breakthroughs: How to Turn $1,000,000 CAR Ts into Real Medicines - Inside Precision Medicine - November 3rd, 2024
- Terumo automates manufacturing to expand cell & gene therapies - European Pharmaceutical Manufacturer - November 3rd, 2024
- 12-Year-Old Leaves Washington DC Hospital As The First Patient To Receive Approved Gene Therapy For Sickle Cell Disease - AfroTech - November 3rd, 2024
- Lexeo Therapeutics Announces Positive Interim Data for - GlobeNewswire - November 3rd, 2024
- New FDA designations granted to NCATS for rare disease therapies. - NCBI - October 22nd, 2024
- $1.8 Million Awarded to Study the Durability of Gene Therapy - University of Arkansas Newswire - October 22nd, 2024
- By the numbers: US leads charge of cell and gene therapies - BioWorld Online - October 22nd, 2024
- University of Arkansas Researcher Awarded $1.8M for Gene Therapy Study - Arkansas Business - October 22nd, 2024
- Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress - StockTitan - October 22nd, 2024
- Around the Helix: Cell and Gene Therapy Company Updates October 16, 2024 - CGTLive - October 22nd, 2024
- Japan mulls ways to boost cell, gene therapy approvals - BioWorld Online - October 22nd, 2024
- A New Type of Gene Therapy Shows Promise for Treating Retinitis Pigmentosa - Managed Healthcare Executive - October 22nd, 2024
- Buy, Sell, Hold: Cell and Gene Therapy - Part 2 - BioPharm International - October 22nd, 2024
- When a Miracle Cure Is Left on the Shelf - Bloomberg - October 22nd, 2024
- Genethon to Showcase the Latest Advances in Gene Therapies for Multiple Diseases at the ESGCT 31 - Business Wire - October 22nd, 2024
- MeiraGTx's gene therapy improves motor function and quality of life in phase 2 Parkinson's trial - Fierce Biotech - October 22nd, 2024
- 5 Sickle Cell Therapies to Watch Following Pfizers Oxbryta Exit - BioSpace - October 22nd, 2024
- Fiocruz and GEMMABio announce partnership for the development of gene therapies - Fiocruz - October 22nd, 2024
- JPMA on Japans Biotech Industry: Cancer, Cardiovascular, and Aging Lead Diseases; Antibody, Cell, and Gene Therapies Top the Innovation List -... - October 22nd, 2024
- Cell and Gene Therapy Clinical Trial Market is expected to reach USD 119.3 Billion by 2032 at a 24.9% of CAGR - PharmiWeb.com - October 22nd, 2024
- Buy, Sell, Hold: Cell and Gene Therapy - Part 3 - Pharmaceutical Technology Magazine - October 22nd, 2024
- The role of quality assurance in accelerating drug development for emerging therapies - pharmaphorum - October 22nd, 2024
- Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress - The Manila Times - October 22nd, 2024
- Nucleic Acid and Gene Therapies in Neuromuscular Disorders Market is projected to grow at a CAGR of - PharmiWeb.com - October 22nd, 2024
- Gene therapy: advances, challenges and perspectives - PMC - October 6th, 2024
- Meeting on the Mesa to Highlight Cell and Gene Therapy Opportunities, Challenges - BioSpace - October 6th, 2024
- Ferring opens doors to Finnish manufacturing hub as supply of its bladder cancer gene therapy continues to grow - FiercePharma - October 6th, 2024
- Meet Boston's National STEM Champion who's a junior in high school studying gene therapy - CBS Boston - October 6th, 2024
- Gene therapy research offers hope for kids with life-altering condition - WCVB Boston - October 6th, 2024
- Is gene therapy the next big step in vision loss treatment? - Medical News Today - October 6th, 2024
- Protein's Role in Insulin Signaling Could Have Implications for Gene Therapy - AJMC.com Managed Markets Network - October 6th, 2024
- Scientists overcome major challenge in gene therapy and drug delivery - News-Medical.Net - October 6th, 2024
- Innovative gene therapy for hemophilia - healthcare-in-europe.com - October 6th, 2024
- The Largest Network of Research Sites Vetted to Execute Complexities of Cell & Gene Therapy (CGT) Trials Now Includes 1,500 Sites - PR Newswire - October 6th, 2024
- Weight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right now - Quartz - October 6th, 2024
- Cell therapy weekly: Promising Phase I results for Parkinsons disease cell therapy - RegMedNet - October 6th, 2024
- Targeting CREB-binding protein (CBP) abrogates colorectal cancer stemness through epigenetic regulation of C-MYC - Nature.com - October 6th, 2024
- Forge Biologics Announces the FUEL AAV Manufacturing Platform to Provide Developers with a More Efficient Solution for Gene Therapy Production -... - October 6th, 2024
- Ninth Circuit Decision Marks Critical Legal Victory for U.S. FDA in Mission to Protect Patients from Unregulated Cell Therapy Products - PR Newswire - October 6th, 2024
- Gene therapy: What is it and how does it work? | Live Science - September 21st, 2024
- How Does Gene Therapy Work? Types, Uses, Safety - Healthline - September 21st, 2024
- In race to make gene therapy for age-related blindness, 4D Molecular announces positive results - STAT - September 21st, 2024
- Penn gene therapy pioneer Jim Wilson explains why he's leaving - The Business Journals - September 21st, 2024
- Whats the Meaning of Cure in Gene Therapy? - Managed Healthcare Executive - September 21st, 2024
- Ori doubles down on Charles River collaboration with promising new data on its automated cell therapy platform - FiercePharma - September 21st, 2024
- Doctors cured her sickle-cell disease. So why is she still in pain? - Nature.com - September 21st, 2024
- Gene Therapy Company Increases Focus on Mesothelioma Program - Mesothelioma.net Blog - September 21st, 2024
- Sickle cell gene therapies roll out slowly : Shots - Health News - NPR - September 21st, 2024
- Patients At Last Begin Receiving Vertex-CRISPR and Bluebird Sickle Cell Gene Therapies - BioSpace - September 21st, 2024
- Beacon Therapeutics Presents 36-Month Interim Results from Phase I/2 HORIZON Trial of AGTC-501 in Patients with XLRP - PR Newswire - September 21st, 2024
- Beacons Gene Therapy Shows Continued Promise in Trial - TipRanks - September 21st, 2024
- How stem cell and gene therapies are revolutionising healthcare - Express Healthcare - September 21st, 2024
- Nanoscope Therapeutics to be Featured at Annual EUretina Congress in Barcelona - PR Newswire - September 21st, 2024
- 6-year-old Tennessee boy denied potentially life-saving gene therapy by insurance company - WCYB - September 21st, 2024
- Seeking a sickle cell cure: 12-year-old in DC is 1st patient in US to get new gene therapy - NBC Washington - May 24th, 2024
- Game-changer: The Hindu Editorial on approval for gene therapy to treat sickle cell disease and beta thalassemia - The Hindu - December 13th, 2023
- Early trials show promise for innovative gene therapy in lung cancer treatment - WJAR - October 16th, 2023
- Cell and Gene Therapy Manufacturing Quality Control Market Growing Trends and Technology Forecast to 2029 |... - SeeDance News - October 16th, 2023
- How Gene Therapy Can Cure or Treat Diseases | FDA - March 21st, 2023
- Genetic Therapies - What Are Genetic Therapies? | NHLBI, NIH - March 21st, 2023
- FDA approves novel gene therapy to treat patients with a rare form of ... - December 28th, 2022
- Gene Therapy - Discover How It Works Its Types And Applications - BYJUS - December 28th, 2022
- IVERIC bio Subsidiary Sells Assets of Gene Therapy Product Candidates for Treatment of Retinal Diseases - Marketscreener.com - December 28th, 2022
- Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th... - October 31st, 2022